Donanemab physiologically based pharmacokinetic model coupled with natural life cycle model for amyloid plaque aggregation to predict target CSF and ISF concentrations associated with amyloid plaque reduction
Increased understanding of the disposition of amyloid-targeting agents in the CNS allows for better understanding of ISF concentrations associated with therapeutic effect.
Authors
- Ivelina Gueorguieva (ORCID: https://orcid.org/0000-0001-5864-8924)
- Ronald B. DeMattos (ORCID: https://orcid.org/0009-0008-7651-1807)
- Sergey Shcherbinin
- Drew W. Butkowski
- John R. Sims
- Dawn A. Brooks
Institutions
- Eli Lilly (United States) (US)
- Eli Lilly (United Kingdom) (GB)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_103434
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00